# Pfizer Inc. (PFE) — Q1-2026 Earnings Results

**Report date:** 2026-05-05 (before market open)  
**Sector:** Health Care / Pharmaceuticals  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/PFE/earnings/Q1-2026

## Analyst Estimates

- **Consensus EPS:** $0.72 (range $0.56–$0.81)
- **Consensus revenue:** $13805.62

## Post-Earnings Brief

### Headline

Pfizer Beats on EPS, Stock Up 0.57%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.75 | $0.72 | +5.63% |
| Revenue | N/A | $13.8B | N/A |

### Management Commentary

**Tone:** Unknown

No transcript is on record for the earnings call, so analysis is based solely on numerical results.

### Guidance Changes

No forward guidance data is available for this quarter.

### What It Means

Pfizer's earnings report shows a positive surprise in EPS, which likely contributed to the stock's modest increase of 0.57%. However, the lack of revenue data and management commentary leaves some uncertainty about the company's overall performance and future outlook.

## Pre-Earnings Brief

### Company Snapshot

Pfizer Inc. is a leading pharmaceutical company known for developing and manufacturing medicines and vaccines. With a market cap of $150 billion, it plays a crucial role in the health care sector, especially in the wake of the COVID-19 pandemic and ongoing health challenges.

### Key Metrics to Watch

- **EPS** (consensus $0.72) — Earnings per share is a key indicator of profitability and helps investors gauge the company's financial health.
- **Revenue** (consensus $13.8B) — Revenue figures provide insight into the company's sales performance and market demand for its products.

### Last Quarter Recap

In Q4 2025, Pfizer reported an EPS of $0.66, exceeding expectations by 16.81%. However, the stock fell 3.34% the following day, indicating market caution despite the earnings beat.

### Wall Street Expectations

Analysts expect Pfizer to report solid earnings, with a consensus EPS of $0.72 and revenue of $13.8 billion. The market is closely watching how the company navigates post-COVID dynamics.

**Bull case:** If Pfizer exceeds EPS expectations, it could signal strong demand for its products and a recovery in its core business, potentially boosting investor confidence.

**Bear case:** Conversely, if the company misses earnings expectations or provides weak guidance, it could raise concerns about its growth trajectory and market position.

### Options Signal

Implied move: **4.2%**

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.

### Earnings Track Record

| Quarter | EPS Surprise | 1-Day Reaction |
|---|---|---|
| Q4-2025 | +16.81% | -3.34% |
| Q3-2025 | +32.22% | -1.46% |
| Q2-2025 | +36.36% | +5.18% |
| Q1-2025 | +43.75% | +3.21% |
| Q4-2024 | +30.98% | -1.26% |

### Pivotal Questions

1. **Will Pfizer's EPS exceed the consensus estimate of $0.72?**
   - Why it matters: A beat on EPS could indicate stronger-than-expected demand for its products and boost investor confidence.
2. **What guidance will management provide regarding future revenue growth?**
   - Why it matters: Future revenue guidance is crucial for assessing the company's growth trajectory and market outlook.

### Thesis Break Levels

- **Bull trigger:** An EPS of $0.75 or higher would confirm strong demand and positive market sentiment.
- **Bear trigger:** An EPS below $0.68 would raise concerns about the company's growth and market position.

This quarter's performance is critical as it reflects Pfizer's ability to sustain growth post-COVID and adapt to changing market conditions.

### Scenario Playbook

- **Beat & raise:** If Pfizer beats expectations, history suggests the stock could rise by around 1.15%, confirming a positive outlook.
- **In-line / cautious:** If results are in line with expectations, the stock may see muted movement as investors await further guidance.
- **Miss:** If Pfizer misses earnings expectations, history suggests a potential decline of about 3.01%, raising concerns about its growth.

### What the Street is Missing

The Street may underestimate the impact of new product launches and ongoing demand for vaccines, which could drive stronger revenue than expected.

**Supporting points:**

- Pfizer has consistently beaten EPS estimates in recent quarters, indicating strong operational performance.
- The options market is pricing a 4.2% move, suggesting expectations of volatility that may not align with actual performance.

**Risk to consensus:** If new product sales significantly exceed expectations, it could challenge the current consensus view.

### What to Listen For

- Any commentary on vaccine demand and sales trends.
- Updates on new product launches and their expected impact on revenue.
- Management's outlook on market conditions and competitive landscape.
- Insights into cost management and operational efficiency.
- Guidance on future earnings and revenue expectations.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/PFE/earnings/Q1-2026_